MitoRainbow Therapeutics Inc is an early-stage company advancing new treatments for mitochondrial diseases. Mitochondria are the “powerhouse” of the cell and generate most of the metabolic energy needed for cells and tissues to function. Mitochondrial diseases are a group of genetic disorders characterized by chronic and progressive loss of function usually in cells and tissues that require the most energy. Patients suffer from a variety of symptoms, including poor growth, difficulty in breathing and/or swallowing, muscle weakness, and vision problems. Certain mitochondrial diseases may be fatal at an early age. MitoRainbow is developing a small-molecule drug, MTR1, as a novel treatment for thymidine kinase deficiency (TK2d). Patients with TK2d are unable to make sufficient mitochondrial DNA (mtDNA). Depletion in mtDNA results in progressive and severe muscle weakness, difficulty in breathing, swallowing, walking and other motor functions. In some cases, TK2d can lead to early death in toddlers and children. MTR1 works by providing the necessary building to overcome mtDNA depletion and thus power the mitochondria back to life.

For inquiries, contact info@mitorainbow.com

FCOI Policies